Previous 10 | Next 10 |
Live moderated video webcast on Thursday, July 13 th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company de...
TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that all ite...
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, t...
2023-05-09 17:46:49 ET Aeterna Zentaris press release ( NASDAQ: AEZS ): Q1 GAAP EPS of -$0.88. Revenue of $2.1M (+40.0% Y/Y). The Company had $46.6 million in cash and cash equivalents at March 31, 2023. For further details see: Aeterna Zentaris GAAP EPS of -...
– Ended the quarter with $ 46 . 6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerat e recruitment for DETECT trial A ctively seeking alternate development and commercializatio...
2023-04-05 08:48:13 ET The shares of nano-cap biotech Aeterna Zentaris ( NASDAQ: AEZS ) lost ~13% pre-market Wednesday after announcing a temporary halt to U.S. sales of its lead product Macrilen (macimorelin), effective May 23, 2023. The temporary move follows last year...
U . S . sales of Macrile n ® for adult use to be temporarily discontinued as of May 23, 2023 , while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen ...
2023-03-23 08:39:54 ET Aeterna Zentaris press release ( NASDAQ: AEZS ): Q4 GAAP EPS of -$2.56. Revenue of $2.5M (+150.0% Y/Y). The Company had $50.6 million in cash and cash equivalents at December 31, 2022. For further details see: Aeterna Zentaris GAAP EPS ...
2023-03-16 08:39:43 ET Aeterna Zentaris ( NASDAQ: AEZS ) said Pharmanovia acquired licensing rights to growth hormone therapy Ghryvelin from Aeterna's existing licensee Consilient Health. Pharmanovia acquired exclusive rights and license to commercialize Ghryvelin (ma...
Pharmanovia to acquire license to GHRYVELIN ™ from Aeter n a Zentaris’ existing licensee, Consilient Health , effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (N...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
2024-05-03 09:02:04 ET Aeterna Zentaris Inc. (AEZS) announced stock split at a ratio of 1-for-4 on 2024-05-03 ... Full story available on KlickAnalytics.com
TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna") and Ceapro ...
TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna ") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“ Ceapro ”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approvin...